XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3
BUSINESS COMBINATION (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Feb. 14, 2024
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Common stock, shares outstanding 164,614,418 170,773,864     170,773,864   119,999,989
Merger transaction costs $ 7,728,681   $ 7,499,353  
Transaction costs charged to equity 229,328            
Issuance of Series B preferred stock $ 3,613,000   $ 3,613,000        
Earnout Shares [Member]              
Earnout shares issuable 24,500,000            
Tevogen Bio [Member]              
Ownership percentage   91.00%     91.00%